- $85.64m
- -$127.68m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.59 | ||
Price to Tang. Book | 0.59 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -123.07% | ||
Return on Equity | -102.85% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 0.17 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Directors
- David Hallal CHM (54)
- Vikas Sinha PRE (57)
- Diana Brainard CEO (50)
- Ann Leen CFD (44)
- Brett Hagen CAO (48)
- Edward Miller GCN (56)
- Ercem Atillasoy OTH (56)
- Jeroen van Beek OTH (57)
- Juan Vera DRC (41)
- Jeffrey Bornstein IND (55)
- Malcolm Brenner IND (69)
- Ansbert Gadicke IND (63)
- Morana Jovan-Embiricos IND (54)
- John Wilson IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 19th, 2013
- Public Since
- July 30th, 2020
- No. of Shareholders
- 54
- No. of Employees
- 112
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 114,153,538
- Address
- 1100 Winter Street, WALTHAM, 02451
- Web
- https://www.allovir.com
- Phone
- +1 6174332605
- Auditors
- Deloitte & Touche LLP
Upcoming Events for ALVR
Allovir Inc Annual Shareholders Meeting
Q2 2024 Allovir Inc Earnings Release
Similar to ALVR
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:01 UTC, shares in Allovir are trading at $0.75. This share price information is delayed by 15 minutes.
Shares in Allovir last closed at $0.75 and the price had moved by -80.15% over the past 365 days. In terms of relative price strength the Allovir share price has underperformed the S&P500 Index by -83.48% over the past year.
The overall consensus recommendation for Allovir is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Allovir does not currently pay a dividend.
Allovir does not currently pay a dividend.
Allovir does not currently pay a dividend.
To buy shares in Allovir you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.75, shares in Allovir had a market capitalisation of $85.64m.
Here are the trading details for Allovir:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ALVR
Based on an overall assessment of its quality, value and momentum Allovir is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Allovir is $1.00. That is 33.3% above the last closing price of $0.75.
Analysts covering Allovir currently have a consensus Earnings Per Share (EPS) forecast of -$0.42 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allovir. Over the past six months, its share price has underperformed the S&P500 Index by -57.82%.
As of the last closing price of $0.75, shares in Allovir were trading -56.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Allovir PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Allovir's management team is headed by:
- David Hallal - CHM
- Vikas Sinha - PRE
- Diana Brainard - CEO
- Ann Leen - CFD
- Brett Hagen - CAO
- Edward Miller - GCN
- Ercem Atillasoy - OTH
- Jeroen van Beek - OTH
- Juan Vera - DRC
- Jeffrey Bornstein - IND
- Malcolm Brenner - IND
- Ansbert Gadicke - IND
- Morana Jovan-Embiricos - IND
- John Wilson - IND